BBA
HARP

Baker Bros. Advisors’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Baker Bros. Advisors’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,447
Closed -$2.37M – 122
2020
Q1 		$2.37M Sell
20,447
-982
-5% -$138K 0.01% 87
2019
Q4 		$3.17M Hold
21,429
– – 0.02% 82
2019
Q3 		$2.93M Hold
21,429
– – 0.02% 76
2019
Q2 		$2.79M Hold
21,429
– – 0.02% 76
2019
Q1 		$2.03M Buy
+21,429
New +$2.82M 0.01% 81

Other funds holding HARP

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors's HARP Position: Q2 2020 in Review

Baker Bros. Advisors sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q2 2020, closing a stake of 20,447 shares — an estimated $2.37M sold.

Baker Bros. Advisors first reported a position in HARP in Q1 2019 and held it in 5 quarters. The position peaked at $3.17M in Q4 2019. 69 funds tracked by Wall St. Rank hold HARP as of Q2 2020.

  • Baker Bros. Advisors reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Baker Bros. Advisors sold 20,447 Harpoon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $2.37M.
  • Baker Bros. Advisors first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q1 2019 and held it in 5 quarters.
  • Baker Bros. Advisors's Harpoon Therapeutics, Inc. Common Stock position peaked at $3.17M in Q4 2019.
  • 69 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.